A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Verdiperstat (Primary)
- Indications Multiple system atrophy
- Focus Registrational; Therapeutic Use
- Acronyms M-STAR
- Sponsors Biohaven Pharmaceutical
- 31 Jul 2019 According to a Biohaven Pharmaceutical Holding Company media release, the first patient has been enrolled in this study.
- 22 Jul 2019 Status changed from not yet recruiting to recruiting.
- 13 Jun 2019 Planned initiation date changed from 15 Jul 2019 to 30 Jul 2019.